The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer

Abstract

BackgroundThe data on immune checkpoint inhibitors (ICI) use in lung cancer individuals generally underrepresented in clinical trials are limited. We aimed to examine the ICI access, safety, and outcome in these populations using real-world data. MethodsPatients with lung cancer newly started on ICIs from 2018 to 2021 were included. Patient factors (age, sex, race, insurance, Charlson comorbidity index (CCI), Eastern Cooperative Oncology Group (ECOG) status, histories of autoimmune disease (AD), infection within 3 months before treatment, and brain metastasis) were collected and grouped. Associations of each patient factor with the time-to-treatment initiation (TTI) of ICIs and immune-related adverse events (irAEs) were examined via cumulative incidence analyses and Chi-squared tests, respectively. Log-rank tests and Cox models were used to assess association of patient factors with overall survival (OS). ResultsOf 125 patients (median age:70 years (50-88), 68 (54.4%) males), 9 (7.2%) had Medicaid/uninsured, 44 (35.2%) had ECOG≥2, 101 (80.8%) had CCI ≥ 3, 16 (12.8%) had ADs, 14 (11.2%) had infections, and 26 (20.8%) had brain metastases. In newly diagnosed stage IV patients (N=62), no difference in TTI was found by patient factors. Fifty irAEs occurred within 12 months and no differences in irAEs occurrence by patient factors. In advanced-stage group (N=123), OS did not differ by patient factors, except for race (p=0.045). Whites showed an inferior OS than non-Whites in multivariable regression. (Hazards ratio=2.82 [1.01-7.87], p=0.047). ConclusionsPreviously poorly represented subgroups were shown to have no significant delays in ICI use, general tolerance, and comparable outcomes. This adds practical evidence to ICI use in clinically and/or socio-demographically marginalized populations.